These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 38880655)

  • 61. How Ligands Illuminate GPCR Molecular Pharmacology.
    Wacker D; Stevens RC; Roth BL
    Cell; 2017 Jul; 170(3):414-427. PubMed ID: 28753422
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Application of computational methods for class A GPCR Ligand discovery.
    Szwabowski GL; Baker DL; Parrill AL
    J Mol Graph Model; 2023 Jun; 121():108434. PubMed ID: 36841204
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Characterizing common substructures of ligands for GPCR protein subfamilies.
    Erguner B; Hattori M; Goto S; Kanehisa M
    Genome Inform; 2010; 24():31-41. PubMed ID: 22081587
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Automated discovery of GPCR bioactive ligands.
    Raschka S
    Curr Opin Struct Biol; 2019 Apr; 55():17-24. PubMed ID: 30909105
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Expanding the horizons of G protein-coupled receptor structure-based ligand discovery and optimization using homology models.
    Cavasotto CN; Palomba D
    Chem Commun (Camb); 2015 Sep; 51(71):13576-94. PubMed ID: 26256645
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Structural diversity of G protein-coupled receptors and significance for drug discovery.
    Lagerström MC; Schiöth HB
    Nat Rev Drug Discov; 2008 Apr; 7(4):339-57. PubMed ID: 18382464
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Molecular modeling of vasopressin receptor and in silico screening of V1b receptor antagonists.
    Hagiwara Y; Ohno K; Kamohara M; Takasaki J; Watanabe T; Fukunishi Y; Nakamura H; Orita M
    Expert Opin Drug Discov; 2013 Aug; 8(8):951-64. PubMed ID: 23682717
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Solution- and solid-state NMR studies of GPCRs and their ligands.
    Tapaneeyakorn S; Goddard AD; Oates J; Willis CL; Watts A
    Biochim Biophys Acta; 2011 Jun; 1808(6):1462-75. PubMed ID: 20951674
    [TBL] [Abstract][Full Text] [Related]  

  • 69. G-protein-coupled receptors oligomerization: emerging signaling units and new opportunities for drug design.
    Tena-Campos M; Ramon E; Rivera D; Borroto-Escuela DO; Romero-Fernandez W; Fuxe K; Garriga P
    Curr Protein Pept Sci; 2014; 15(7):648-58. PubMed ID: 25175459
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Structure-based drug design for G protein-coupled receptors.
    Congreve M; Dias JM; Marshall FH
    Prog Med Chem; 2014; 53():1-63. PubMed ID: 24418607
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Structure-based drug screening for G-protein-coupled receptors.
    Shoichet BK; Kobilka BK
    Trends Pharmacol Sci; 2012 May; 33(5):268-72. PubMed ID: 22503476
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Structural models of class a G protein-coupled receptors as a tool for drug design: insights on transmembrane bundle plasticity.
    Deupi X; Dölker N; López-Rodríguez ML; Campillo M; Ballesteros JA; Pardo L
    Curr Top Med Chem; 2007; 7(10):991-8. PubMed ID: 17508932
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pilot the pulse: controlling the multiplicity of receptor dynamics.
    Bock A; Kostenis E; Tränkle C; Lohse MJ; Mohr K
    Trends Pharmacol Sci; 2014 Dec; 35(12):630-8. PubMed ID: 25455830
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Conformational Basis of G Protein-Coupled Receptor Signaling Versatility.
    Wingler LM; Lefkowitz RJ
    Trends Cell Biol; 2020 Sep; 30(9):736-747. PubMed ID: 32622699
    [TBL] [Abstract][Full Text] [Related]  

  • 75. PREDICT modeling and in-silico screening for G-protein coupled receptors.
    Shacham S; Marantz Y; Bar-Haim S; Kalid O; Warshaviak D; Avisar N; Inbal B; Heifetz A; Fichman M; Topf M; Naor Z; Noiman S; Becker OM
    Proteins; 2004 Oct; 57(1):51-86. PubMed ID: 15326594
    [TBL] [Abstract][Full Text] [Related]  

  • 76. New tools for G-protein coupled receptor (GPCR) drug discovery: combination of baculoviral expression system and solid state NMR.
    Ratnala VR
    Biotechnol Lett; 2006 Jun; 28(11):767-78. PubMed ID: 16786240
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Increasingly accurate dynamic molecular models of G-protein coupled receptor oligomers: Panacea or Pandora's box for novel drug discovery?
    Filizola M
    Life Sci; 2010 Apr; 86(15-16):590-7. PubMed ID: 19465029
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Advances in Computational Techniques to Study GPCR-Ligand Recognition.
    Ciancetta A; Sabbadin D; Federico S; Spalluto G; Moro S
    Trends Pharmacol Sci; 2015 Dec; 36(12):878-890. PubMed ID: 26538318
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Docking-based virtual screening for ligands of G protein-coupled receptors: not only crystal structures but also in silico models.
    Vilar S; Ferino G; Phatak SS; Berk B; Cavasotto CN; Costanzi S
    J Mol Graph Model; 2011 Feb; 29(5):614-23. PubMed ID: 21146435
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Mass-spectrometry-based method for screening of new peptide ligands for G-protein-coupled receptors.
    Cologna CT; Gilles N; Echterbille J; Degueldre M; Servent D; de Pauw E; Quinton L
    Anal Bioanal Chem; 2015 Jul; 407(18):5299-307. PubMed ID: 25935673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.